AI Disclosure: This research was conducted by a coordinated team of specialized AI research agents under human direction. Every factual claim cites a specific published source. The evidence was independently verified by two specialized AI reviewers using structured pair review with documented pushback. This is educational content — not medical advice. Always discuss treatment decisions with your healthcare provider.

Print the CARE Brief to bring to your doctor visit.

Part 1 — The Condition

What Peyronie's Disease Is

Peyronie's disease (PD) is a wound-healing disorder of the tunica albuginea — the tough collagen sheath around the erectile bodies. In genetically predisposed men, penile trauma triggers abnormal scarring: instead of resolving, the scar tissue keeps building. The result is a fibrous plaque that restricts normal expansion during erection, causing curvature, deformity, and often pain (Kadioglu 2011). Important: only 29% of patients recall a specific traumatic event (Paulis 2024) — most PD occurs without remembered trauma. If you don't remember an injury, that does NOT rule out PD.

How common: 3-9% of adult men. Likely underreported because men are reluctant to seek care. 24% of patients are ≤40 years old — younger than previously thought (Paulis 2024, n=564). Note: PD doesn't always present with visible curvature — the CUA guideline (Bella 2018) describes atypical PD (penile septal scar) causing ED and pain WITHOUT palpable deformity or curvature.

Two phases:

• Acute (active): Progressive deformity — curvature and/or plaque still evolving. Pain may or may not be present. There is no fixed timeline (ICSM 2024 explicitly: "no universally agreed-upon definition of the acute phase"). The old "12-18 months" framing has been abandoned by the most current guideline. Active phase is defined by whether deformity is still progressing, not by how many months have passed. Paulis 2024 documented active disease at 22-26 months — with pain already resolved but curvature still worsening.

• Stable (chronic): Curvature stops changing (no change for ≥3 months). Pain may still be present in stable phase — "pain with erection may be present due to torque or stretch on the penile scar" (ICSM 2024). Pain resolution alone does NOT confirm stability.
• Surgical eligibility requires stable phase for at least 6 months (ICSM 2024 Rec #18) — this is a higher threshold than the 3-month phase definition.
• Penile shortening is the most common deformity (88.2%, Paulis 2024) — more than 70% of patients report shortening BEFORE any surgery (Osmonov ESSM 2022). The disease causes the shortening, not surgery.
• Multifocal plaque occurs in 16.1% (Paulis 2024).

The defining question is not "how many months has it been?" — it is whether curvature is still progressing. Active phase is determined by ongoing change, not elapsed time. A patient whose curvature continues to worsen — even at 24 months — is in active phase by the most current definition.

Understanding Your Doppler Results

A penile Doppler ultrasound (also called a penile duplex ultrasound) is the standard imaging study for evaluating Peyronie's disease. Performed with a pharmacological injection to induce erection, it allows the urologist to measure the curvature directly, examine the plaque, assess blood flow, and evaluate erectile response in one visit.

What a standard Doppler assesses:

• Curvature angle and direction — measured with a goniometer at the point of maximum deviation. Direction is dorsal (upward), lateral (left/right), ventral (downward), or complex.
• Plaque characteristics — location along the shaft (proximal, mid-shaft, distal), size, and calcification status (none, stippled, or dense).
• Vascular parameters — peak systolic velocity, end-diastolic velocity, time to peak flow, and arterial diameter, assessed bilaterally. These distinguish a vascular cause of erectile difficulty from a non-vascular one.
• Venous phase — minimal flow during the venous phase indicates the veins are closing properly. This is the desired finding; significant venous flow can suggest venous leak.
• Erectile response with injection — graded as a percentage of full rigidity. A strong response means the patient is a candidate for non-prosthesis treatments.

Reference table — what your Doppler findings mean

What your Doppler report may NOT cover

A Doppler report is only as complete as the assessments performed during the study. Several findings are clinically important but are frequently absent from PD Doppler reports:

• Volume-loss deformity (hourglass, indentation, axial instability) — Margolin 2018 (n=128) found these in 65% of PD patients, yet they are commonly not assessed or documented. Volume-loss deformities are clinically important: their presence may actually predict a better response to CCH (see Part 3A "Predictors of CCH Response").
• Calcification grading — some reports note "no calcification" without specifying whether grading was performed. If calcification status is unclear, ask your urologist whether it was specifically assessed.
• Bilateral comparison — vascular parameters should be measured on both sides. A unilateral assessment may miss asymmetry that is clinically meaningful.

If any of these are missing from your report, that is itself a finding worth raising with your urologist. A complete Doppler is the foundation of an evidence-based treatment plan.

What Doppler contributes to the ED picture

Erectile difficulty in PD has three potential origins: vascular (a blood-flow problem), PD-secondary (caused by the disease itself — curvature, plaque, anxiety about the appearance), or psychogenic. A Doppler resolves the vascular component: normal arterial flow and venous closure on Doppler argue against an independent vascular cause. The remaining distinction (PD-secondary vs psychogenic) is informed by clinical history, validated questionnaires, and partner assessment — not by Doppler alone.

This matters because 56.4% of PD patients with ED had ED before developing PD (Paulis 2024). For some patients, treating the PD alone will not fully resolve the ED. A Doppler is the start of the ED workup, not the conclusion.

The Psychological Reality

This is hard. The research confirms it:

• 88.4% of active-phase PD patients presenting to a specialist andrology clinic reported significant anxiety (GAD-7 >9, Paulis 2024 n=564 — note: 99.1% Caucasian, Italian single-center, specialist-seeking high-bother population; community rates and other demographics may differ)
• Rates of depression vary by instrument and population: 27% on CES-D ≥16 (Punjani 2021, n=408); 47% as reported by Nelson and cited in CUA guidelines (Bella 2018 — instrument not specified in guideline text); 57.6% on PHQ-9 >9 in an active-phase specialist clinic (Paulis 2024, n=564). The range (27-58%) reflects different instruments, thresholds, and populations — not contradictory findings.
• Depression is driven by bother and self-image, NOT by curvature degree — IIEF does not significantly correlate with curvature severity (p=0.359), plaque volume (p=0.09), or disease duration (p=0.554) (Paulis 2024, Table 7). This independently confirms Goldstein 2017's finding that improvement tracks with reduced bother, not mechanical correction.
• Being partnered is protective against depression (OR 0.42, Punjani 2021)
• 56.4% of PD patients with ED had ED BEFORE developing PD (Paulis 2024) — ED is not always PD-caused. For patients whose ED partially predates PD, treating the PD alone may not fully resolve it.
• Psychotherapy is clinically recommended: Paulis 2024 (n=564) concludes that "psychotherapy should be integrated into the treatment of PD patients to enhance quality of life and discourage them from discontinuing ongoing medical therapies." This isn't optional emotional support — it helps people stay on treatment. Patients may want to ask their urologist about a mental health referral.
• Partners are affected too: 75% of female partners of men with PD met criteria for sexual dysfunction before treatment (Goldstein 2017)

This is the norm for PD patients, not a personal weakness. Treatment — even modest improvement — reduces bother and restores sense of agency, which drives quality-of-life improvement independently of curvature change. (See Evidence Reference §1.6)

Part 2 — Treatment Options

The Evidence Hierarchy — What Actually Works

The evidence hierarchy puts CCH and traction at the top. Verapamil has no controlled curvature evidence.

Tier 1: Strong controlled evidence

CCH (Xiaflex) — The only FDA-approved PD injection. Two large double-blind RCTs (IMPRESS, n=832) plus two meta-analyses confirm significant curvature improvement. (Detailed in Part 3A)

Tier 2: Positive controlled evidence, but guidelines oppose routine use

Hyaluronic Acid (HA) — Two double-blind RCTs show it outperforms verapamil. No significant or lasting adverse events reported. But ICSM 2024 (5th Consultation) recommends AGAINST routine HA use outside clinical trials, and EAU guidelines recommend against routine use. Approved only in Italy. (Detailed in Part 3B)

Tier 3: Supported by RCT, immediately actionable

RestoreX traction — RCT (n=100): -11.7° curvature improvement at just 30-90 min/day. Can start NOW — no prescription needed, no phase requirement. ICSM 2024 upgraded traction to Conditional Recommendation with Moderate Quality of Evidence — the most current major-society endorsement. (Detailed in Part 3C)

Tier 4: Reasonable adjunct, limited curvature evidence

Tadalafil daily (5 mg) — Does NOT prevent curvature progression (Durukan 2024, P=.08). MAY shorten pain duration (9.1 vs 12.2 months, P=.04). Supports ED and penile oxygenation. Part of the Mayo Clinic oral protocol: pentoxifylline + L-citrulline + tadalafil. (See Evidence Reference §2.2)

Tier 5: No controlled curvature evidence

Verapamil injection — Two double-blind RCTs have tested verapamil head-to-head with HA, and verapamil was significantly inferior in both: Favilla 2017 (n=140, verapamil 0.00° ± 0.00 vs HA -4.60°, P<.001) and Abdel Fattah 2024 (n=42, verapamil -5.4° vs HA -9.4°, P=.038). No placebo-controlled trial has tested verapamil alone. Uncontrolled studies report improvement (e.g., Levine 2002, n=156: 60% "objectively improved") but lack placebo arms.

Tier 6: Surgical options (if conservative treatment fails)

Plication, grafting, prosthesis — Gold standard for stable-phase PD with significant curvature. Plication does NOT cause additional length loss beyond what PD itself produces (Garaffa 2024, n=91, abstract only). Perception gap: Hudak found 84% had no measurable decrease in stretched penile length, but 78% perceived length reduction — the gap between measurement and perception is large and important for surgical counseling. Prior CCH does NOT increase surgical complications. Important expectations: Grafting curvature recurrence: 50-87% in longer-term follow-up (Osmonov ESSM 2022). Even with prosthesis, >25% of patients were dissatisfied with straightness despite achieving <20° residual curvature in the OR — "functionally straight" may not match patient expectations (Ziegelmann 2020). Note: surgical ED outcome data across most studies uses the IIEF questionnaire, which has not been validated for PD (Osmonov 2022) — ED rates are indicative, not precise. (See Evidence Reference §2.6)

Questions to Discuss With Your Doctor Before Self-Directed Treatment

PD has evidence-supported options that some patients pursue alongside or before prescription treatment. Before self-directing any of these, the safer path is to bring the evidence to your doctor and ask whether the option is appropriate for your specific situation.

• Penile traction therapy. A counter-bending traction device (RestoreX) showed -11.7° curvature improvement at 30-90 min/day for 3 months in RCT data (Ziegelmann 2019, n=100). ICSM 2024 issued a Conditional Recommendation for traction therapy with Moderate Quality of Evidence. The shorter time commitment is specific to the counter-bending design — older devices required 3-8 hours/day. Ask your doctor: "Is traction therapy appropriate for my phase and situation? Which device does the published evidence specifically support?"

• Tadalafil daily. Does not prevent curvature progression (Durukan 2024, P=.08) but supports penile oxygenation and is a component of the Mayo Clinic oral PD protocol (Ziegelmann 2020). Ask your doctor: "Would daily tadalafil be appropriate for me, and at what dose?"

These are starting points, not a complete plan. The full treatment strategy depends on phase, curvature characteristics, and personal priorities — discussed with the urologist using the framework in Part 4.

Part 3 — Deep Dive: The Three Realistic Options

Part 3A — CCH (Xiaflex): The Strongest Evidence

What it is: A bacterial enzyme that breaks down the collagen in PD plaques. The only FDA-approved injection for PD.

How well it works:

• IMPRESS trials (n=832): 34% curvature improvement vs 18% placebo. The AUA guideline calls this "a modest difference of 7.7°" — honest framing (Gelbard 2013).
• Pooled across 11 studies (n=1,480): 35% improvement with zero heterogeneity — remarkably consistent (Zhang 2022).
• Less than half respond by strict criteria: In IMPRESS phase III, only 46% met the composite responder definition (≥20% curvature improvement + >1-point PDQ bother reduction). Flores 2022 (n=114, different metric): 44% improved, 39% no change, 17% worsened. Both measures converge: fewer than half of CCH patients achieve clinically meaningful improvement.
• Important: These rates are from pre-selected favorable populations — IMPRESS excluded hourglass deformity, ED, ventral curvature, and significant calcification. Real-world patients are less pre-selected.
• Real-world gap: Post-approval community data (Tsambarlis, per Ziegelmann 2020, n=45) found only 5.4° mean improvement vs IMPRESS's 17° — trial results don't always translate to community practice.
• ⊕ NEW: Trost-protocol outcomes (Cahill 2025, n=826): With aggressive modeling + 0.9mg dose + RestoreX, median improvement was 27.5-32.5° — nearly double IMPRESS. These are NOT standard CCH results — they require the specific Trost protocol. ⚠️ Triple COI: Trost is RestoreX inventor + PathRight part-owner + Endo-funded. Confound: 98% used RestoreX, insufficient non-use power to isolate its independent effect.

Predictors of CCH Response

Recent evidence has identified clinical factors that predict how a patient is likely to respond to CCH. These are general predictors that any PD patient and their urologist can apply to estimate likely benefit before starting treatment.

• Curvature direction: Dorsal curvature shows the highest response rate — approximately 50% median improvement vs 33.6% for ventral curvature (Lumbiganon 2025, n=292). Lateral curvature is associated with 11° worse outcomes than dorsal in multivariate analysis (Cahill 2025, P<.001).
• Baseline curvature degree: Greater baseline curvature predicts greater absolute improvement. Per 10° increase in baseline, the odds of clinically meaningful improvement increase (OR 1.33, Flores 2022). Cahill 2025 (n=826) found 0.5° greater curvature improvement per 1° increase in baseline curvature (P<.0001, multivariate).
• Volume-loss / hourglass deformity: Counter to the historical assumption that hourglass deformity limits CCH candidacy, recent evidence shows the opposite. Cahill 2025 (n=826, multivariate P=.02) found that moderate or severe hourglass/indentation deformity predicts 3-10° MORE curvature improvement than absent or mild volume-loss. Patients with these features were excluded from the original IMPRESS trials, but real-world data suggests they may be among the best responders.

• Calcification status: Historically, calcification was considered a barrier to CCH treatment. However, the largest published CCH outcomes study (Cahill 2025, n=826) found no significant association between calcification and treatment failure (P=.37). Calcification alone should not exclude a patient from CCH consideration.
• Concurrent RestoreX traction: Adding RestoreX to CCH is associated with a 19.5° greater curvature improvement in multivariate analysis (Cahill 2025, P=.02), and CCH+RestoreX patients are 6.9× more likely to achieve ≥20° improvement than CCH alone (Alom 2019, abstract). RestoreX was the strongest predictor of all factors assessed in Cahill 2025 — though confounded with concurrent protocol changes (98% of the cohort used it).

• Disease phase: Active phase is NOT a barrier to CCH response. Cahill 2025 (P=.48, NS) and Cocci 2020 (-19.3°, n=74) both support CCH efficacy in active disease. The FDA label specifies stable-phase use, but the clinical evidence does not support phase as a discriminator of response.

These predictors are not categorical eligibility rules — they are factors a patient and urologist can weigh together when discussing whether CCH is likely to help.

The protocol:

• Standard (IMPRESS): 4 cycles × 2 injections = 8 injections over 24 weeks. Cost: ~$15,000-18,000 total before insurance.
• Shortened (Ralph): 3 injections at 4-week intervals. Similar efficacy, lower cost (Capece 2018, n=135).

• Cycle-2 decision point: If no improvement after 4 injections, continuing offers minimal additional benefit (Flores 2022; Anaissie 2017 cited via Lumbiganon 2025).
• Modeling is NOT optional. CCH without structured modeling produces minimal benefit. The placebo arm in IMPRESS improved by 9.3° — likely FROM modeling alone.

Side effects:

• Expected (nearly universal): 84.2% of CCH patients had at least one adverse event vs 36.3% placebo (IMPRESS, per AUA guideline Nehra 2015). Bruising (60-93%), pain (34%), swelling (30%). Most mild/moderate, resolve within 14 days.
• Serious (rare): penile fracture — IMPRESS: 0.36% (3/832). Lumbiganon: 1.4% (4/292 with intensive 3×/day modeling). Real but rare.
• No sexual activity for 2 weeks after each injection cycle (per Endo Pharmaceuticals product label / IMPRESS protocol; not directly cited in the in-registry papers).

Guideline status: EAU gives the strongest endorsement (Level 1b, Strong). AUA, CUA, ISSM all support. CCH is withdrawn outside the USA — US-only availability.

(See Evidence Reference §3A for full study-by-study data)

Part 3B — Hyaluronic Acid (HA): Positive Data, Guideline Opposition

What it is: A naturally occurring molecule in connective tissue. Anti-inflammatory and anti-fibrotic. NOT FDA-approved for PD.

How well it works:

• Favilla 2017 (double-blind RCT, n=140): HA -4.6° vs verapamil 0.0° (P<0.001). The definitive head-to-head.
• Abdel Fattah 2024 (double-blind RCT, n=42): HA -9.4° vs verapamil -5.4° (P=.038).
• Cilio 2024 (stable phase, n=62): -12.4° with multimodal mechanics (vacuum + stretching + modeling).

The critical caveat: Despite this positive RCT data, ICSM 2024 (5th Consultation) recommends AGAINST routine HA use outside clinical trials, and EAU guidelines recommend against routine use. These guideline committees reviewed the same papers cited here. Their judgment: the evidence base (small samples, no placebo-only trials of HA alone, heterogeneous protocols) is not yet sufficient for routine recommendation. Only approved for PD in Italy.

What this means in practice: Pursuing HA means going against current major guidelines. That's a legitimate choice — guidelines aren't mandates — but a urologist offering HA should be able to articulate why they diverge from the recommendations. If they can't, that's a flag.

Safety: The cleanest profile of any PD injection. No significant or lasting adverse events reported across ALL studies (>600 patients). No fracture risk. No bruising. (See Evidence Reference §3B)

Part 3C — RestoreX Traction: What the Evidence Shows

What it is: A penile traction device with a counter-bending mechanism. The only traction device with positive RCT data at a practical time commitment.

How well it works:

• Ziegelmann 2019 RCT (n=100): -11.7° curvature improvement vs +1.3° in controls. +1.5 cm length gain. 30-90 min/day for 3 months (Ziegelmann 2019, abstract).
• When combined with CCH: 6.9× more likely to achieve ≥20° improvement vs CCH alone (Alom 2019, abstract).
• First study showing benefit at <3 hours daily — prior devices required 3-8 hours.

Why start now:

• No prescription needed.
• No phase requirement — works in both acute and stable.
• Independent benefit whether or not CCH or HA is pursued.
• The counter-bending mechanism specifically targets curvature correction — conventional traction devices did NOT show the same CCH-enhancement effect.

(See Evidence Reference §3C)

Part 3D — Verapamil

The evidence:

• Two double-blind RCTs have tested verapamil head-to-head with HA. Verapamil was significantly inferior in both. Favilla 2017 (n=140): verapamil 0.00° ± 0.00 vs HA -4.60° (P<.001). Abdel Fattah 2024 (n=42): verapamil -5.4° vs HA -9.4° (P=.038). No placebo-controlled trial has tested verapamil alone.
• Uncontrolled studies report improvement (e.g., Levine 2002, n=156: 60% "objectively improved") but lack placebo arms.
• Standard published protocols use weekly to biweekly intervals. Intervals beyond this have no published evidence base.

Why urologists sometimes choose verapamil: Cost ($60/year vs $15,000+ for CCH), availability, safety, and ability to use in acute phase. These are practical advantages. They don't overcome the absence of controlled curvature efficacy.

Guideline status: AUA says "may consider" (Conditional, Grade C) but calls the evidence "weak" and notes "the availability of other treatments that are clearly more effective." EAU recommends AGAINST (Level 4). CUA recommends (Level 3, Grade C — outlier, practice-based: "more than two decades of experience," not controlled evidence). ICSM: Conditional, "may reduce curvature in SOME patients." (See Evidence Reference §3D)

Part 4 — Decision Framework by Phase

The Phase Question

Treatment selection in PD depends primarily on disease phase: active (curvature still progressing) vs stable (curvature unchanged for ≥3 months). Each phase has different treatments with controlled evidence behind them.

The older clinical framing — that the "acute phase" lasts 12-18 months and patients should "wait and see" until then — has been abandoned. ICSM 2024 explicitly notes there is "no universally agreed-upon definition of the acute phase," and the field has shifted to defining phase by what the disease is doing, not by how long it has been doing it. A patient at 24 months whose curvature continues to worsen is in active phase; a patient at 6 months whose curvature has been stable for 3 of those months is in stable phase.

Phase classification ≠ surgical eligibility. Phase classification requires ≥3 months of stability. Surgical eligibility requires ≥6 months of stability per ICSM 2024 Recommendation #18 — a higher threshold. A patient who has just transitioned to stable phase is not yet a surgical candidate.

Treatment Options by Phase

This table summarizes which treatments have evidence for which phases. The cell descriptors are defined below.

Cell descriptor legend:

• Recommended: Major guidelines support and there is controlled evidence in this phase.
• Off-label viable: The treatment has clinical evidence in this phase, but the FDA label or formal guideline does not specify it. Some urologists offer it; insurance may resist.
• Positive evidence; guidelines oppose: RCTs show benefit but major guidelines recommend against routine use outside clinical trials. Pursuing this means knowingly diverging from current guidelines.
• Reasonable adjunct: Limited curvature evidence but reasonable to use alongside primary treatment for related symptoms (ED, pain, oxygenation).
• Recommended for pain: Helps a specific symptom but does not address curvature.
• No controlled curvature evidence: No controlled trial supports curvature benefit. Some guidelines may still permit use based on uncontrolled data; see the Key Evidence column for guideline positions.

Combination evidence (footnote):

• CCH + RestoreX: Patients receiving both are 6.9× more likely to achieve ≥20° improvement than CCH alone (Alom 2019, abstract); 19.5° greater curvature improvement in multivariate analysis (Cahill 2025, P=.02). RestoreX was the strongest predictor of CCH response in Cahill 2025. Triple COI on the Trost protocol (Trost is RestoreX inventor + PathRight part-owner + Endo-funded); 98% RestoreX use in the cohort limits the ability to isolate its independent effect.

What Your Appointment Should Clarify

These are the assessments and questions that change the treatment path. Patients should ensure each is addressed at the visit:

Patient Self-Advocacy and Questions to Discuss

Two of the items in this list are patient self-advocacy actions that any patient can take. The remaining items are evidence-supported options to discuss with your doctor before pursuing on your own.

Self-advocacy actions you can take now

1. Document curvature with photographs over time. Erect photographs from multiple angles, consistent lighting, dated. This becomes objective evidence of progression (or stability) and supports phase determination at follow-up appointments.

2. Request your full medical records from your treating urologist — chart notes, physical exam documentation, AND the Doppler scan images (not just the written report). These are your records (HIPAA-guaranteed in the United States). A second-opinion urologist or any future provider needs the complete picture, including what was not assessed.

Questions to discuss with your doctor before self-directed options

3. Penile traction therapy. RCT evidence supports the RestoreX counter-bending device: -11.7° curvature improvement at 30-90 min/day for 3 months (Ziegelmann 2019, n=100). No phase restriction in the trial. ICSM 2024 Conditional Recommendation, Moderate Quality. Ask your doctor: "Is traction therapy appropriate for my phase and situation? Which device does the published evidence specifically support?"

4. Mayo Clinic oral protocol — supplement component. L-citrulline is one of three components of the published Mayo oral PD protocol (Ziegelmann 2020). The other two components (pentoxifylline, tadalafil) require a prescription. Ask your doctor: "Is the Mayo oral protocol appropriate for me? What dose of L-citrulline is supported by the evidence, and what about the prescription components?"

5. NSAIDs for erection pain in active-phase PD. All four major guidelines (AUA, EAU, ICSM, CUA) support NSAID use for active-phase pain. NSAIDs do not address curvature but address comfort. Ask your doctor: "Are NSAIDs appropriate for my pain, and which one and dose?"

A note on topical verapamil: even for patients seeking an inexpensive alternative, the evidence does not support it. Topical verapamil does not penetrate the tunica albuginea (Martin et al.) and all four major guidelines recommend against it.

Part 5 — What to Watch For at the Appointment

Red Flags in the Urologist's Response

Green Flags

• They perform in-office curvature assessment with pharmacological erection + goniometer (only 60% of urologists do this — Brant 2023, n=145 from 12,018 surveyed)
• They assess for volume-loss deformities without being asked
• They know what Favilla 2017 showed
• They discuss CCH with RestoreX as a combination
• They are fellowship-trained in andrology/sexual medicine (only 19% of PD-treating urologists are — fellowship-trained specialists are significantly more likely to use evidence-based treatments across every measured category)

Why fellowship training matters: Brant 2023 found that 81% of urologists treating PD have NO fellowship in andrology/sexual medicine. Every evidence-based practice measured — CCH use, traction, in-office assessment, duplex ultrasound — was significantly more common in fellowship-trained physicians (P<0.005 for all). Even among urologists who say they follow AUA guidelines, 21% still use explicitly discouraged treatments. The 21% figure likely underestimates the real gap: the survey had a 1.2% response rate, and evidence-unaware urologists are least likely to respond to evidence-practice surveys. Younger urologists (<20 years practice) are more evidence-based than older colleagues across CCH, NSAIDs, and traction use.

Where to Find the Evidence

Every claim in this document traces to a specific study in the Evidence Reference (Document B). When a claim cites (Author Year), look it up in the Evidence Reference for: study design, sample size, methodology, exact numbers, and limitations.

The Evidence Reference is organized to match this document section-by-section:

• §1 = Part 1 (The condition)
• §2 = Part 2 (Treatment landscape)
• §3A-D = Part 3 (Deep dive drugs)
• §4 = Part 4 (Decision framework)
• §5 = Part 5 (Red/green flags)